Why Might This Play Shake Up the Cancer-Drug Industry?
Mike is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Medical firm Johnson & Johnson (NYSE: JNJ) recently announced a private-company acquisition that could have major implications for one of the markets in which it operates. According to reports, the company will acquire the bulk of San Diego-based Aragon Pharmaceuticals by the end of the third quarter of 2013. As a smaller firm that manufactures an experimental-stage drug that fights a particularly aggressive form of prostate cancer, Aragon presents a sizable risk for Johnson & Johnson. At the same time, a successful transition could position the company as the dominant firm in the fast-growing market for prostate cancer drugs.
This purchase could have an impact outside of the Johnson & Johnson ecosystem. Since several companies are in the process of developing experimental prostate drugs, a concerted push by Johnson & Johnson could weed out weaker competitors or reorder the way in which the sub-industry operates. Investors who normally avoid "speculative" pharmaceutical plays might find something to appreciate in this pending deal.
Johnson & Johnson and the Competition
Although Johnson & Johnson has a major pharmaceutical operation and is responsible for providing the drugs that fill millions of prescriptions on an annual basis, it is also a consumer-products firm that produces a stunning array of everyday personal care aids and over-the-counter medications. However, this analysis focuses exclusively on Johnson & Johnson's work in the cancer-drug sector. As such, it would be useful to compare the firm to other pharmaceutical giants that operate in the space.
Johnson & Johnson has a market cap of about $237 billion. By comparison, Swiss competitor Novartis (NYSE: NVS) is valued at around $174 billion. New York-based Pfizer's (NYSE: PFE) valuation comes in at about $205 billion. All three of these firms enjoy eye-popping revenues and solid profits. In 2012, Johnson & Johnson posted a profit of $10.5 billion on revenues of nearly $69 billion. With $9.7 billion in profits on $58 billion in revenues, Novartis had a nearly identical margin. Pfizer posted a $10.5 billion profit on $58 billion in revenues for a substantially better margin.
Thanks in part to its diversification and the promise of its experimental-drug pipeline, Johnson & Johnson is a bit more expensive than its peers. Its price-to-book ratio of 3.6 compares to nearly identical ratios of 2.5 and 2.6 for Pfizer and Novartis.
How the Deal Will Occur
According to a release that accompanied the deal's announcement, Johnson & Johnson will shell out about $650 million in cash for the prostate cancer portion of Aragon's operations. If Aragon's pre-negotiated sales and development targets are met, this payment could be followed by a subsequent $350 million bonus. It should be noted that Johnson & Johnson will not purchase Aragon in its entirety. The company's non-prostate assets will be spun off into a new private concern known as Seragon Pharmaceuticals. This firm will continue to operate with members of Aragon's San Diego-based management team. While this new firm could provide some future investment opportunities as an IPO candidate or buyout target, most market-watchers believe that Aragon's prostate cancer operations are the most valuable piece of its business.
What It Means for Johnson & Johnson and Aragon
The Aragon acquisition opens a number of doors for Johnson & Johnson. If the company's signature prostate drug successfully completes its remaining trial phases, it will enjoy patent exclusivity until the late 2020s. Conveniently, it could also offset the expected loss of revenue from the 2016 patent expiration of Johnson & Johnson's blockbuster Zytiga cancer treatment.
The future looks bright for Aragon's treatment. In early trials, the drug has successfully reduced the size and aggressiveness of early-stage prostate tumors and may actively impede the process by which the cancer typically metastasizes. If these results are borne out by future trials, the drug could represent a powerful new alternative to aggressive radiation therapy, chemotherapy or castration surgery. Such "disruptive" drugs can be worth several billion dollars per year in revenue.
What It Could Mean for Competitors
Johnson & Johnson's aggressive play will have ramifications for all of the cancer-focused firms with which it competes. This deal's biggest impact may well be felt by Medivation, a smaller firm that produces a successful, recently commercialized prostate cancer treatment. Medivation claims that it owns the rights to Aragon's compound and has been pursuing a variety of legal actions to exercise this supposed prerogative. Obviously, Aragon does not agree with this sentiment. Johnson & Johnson's acquisition will bring virtually unlimited resources to this legal fight and provide Aragon's drug with an open-ended development commitment. As such, Medivation may soon find itself struggling to keep pace with its larger competitor.
Is There a Play Here?
Investors who wish to play this deal should look to buy Johnson & Johnson's stock on temporary weakness. Although this acquisition will not produce sustained income for several years, the wait could easily turn out to be worthwhile. In the meantime, Johnson & Johnson offers a solid yield and has plenty of other strong points. While a late-stage failure could temporarily set the firm back, Johnson & Johnson is too powerful to ignore.
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
Mike Thiessen has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!